---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-010964"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T18:08:48.185377+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omeros Q2 OMIDRIA rev $28.8M (+37% QoQ); narsoplimab PDUFA Oct 17

## Summary
- OMIDRIA revenue $28.8M in Q2 2021, up 37% from Q1 $21.1M; net loss narrowed to $28.6M ($0.46/sh) from $35.1M.
- Narsoplimab BLA for HSCT-TMA under FDA priority review with PDUFA action date Oct 17, 2021.
- Preliminary Phase 1 data for OMS906 (MASP-3 inhibitor) show well tolerated, PK/PD consistent with monthly SC dosing.
- CMS proposed rule reaffirms separate payment for OMIDRIA in ASCs for 2022.
- Cash & investments $73.7M; $150M ATM program available; $50M line of credit.

## SEC filing metadata
- accession: 0001558370-21-010964
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000155837021010964/0001558370-21-010964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000155837021010964/omer-20210809x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-010964
- JSON: https://secwatch.observer/filing/0001558370-21-010964.json
- Plain text: https://secwatch.observer/filing/0001558370-21-010964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.